Robert Besser
04 Dec 2022, 08:04 GMT+10
WASHINGTON D.C.: According to trial data contained in a report presented this week, an experimental Alzheimer's drug from Eisai and Biogen, lecanemab, slowed cognitive decline, but could cause serious side effects for certain patients.
In the 18-month trial involving nearly 1,800 participants with early-stage Alzheimer's, Lecanemab was possibly the cause of a dangerous type of brain swelling in nearly 13 percent of patients.
Five patients also suffered from macrohemorrhages and 14 percent from microhemorrhages, which could have caused two deaths in a follow-on study.
In September, the two companies said that lecanemab, an antibody designed to remove sticky deposits of a protein called amyloid beta, reduced the rate of cognitive decline on a clinical dementia scale (CDR-SB) by 27 percent, compared to a placebo.
However, Dr. Ronald Petersen of the Mayo Clinic in Rochester, Minnesota said, "All of these amyloid-lowering drugs carry a risk for increased brain hemorrhage."
The data confirms the drug "can meaningfully change the course of the disease," said the Alzheimer's Association, calling on U.S. regulators to approve the company's application for accelerated approval.
Detailed data from the study was presented at the Clinical Trials on Alzheimer's Disease meeting in San Francisco.
The U.S. Food and Drug Administration (FDA) will decide whether to approve lecanemab under its "accelerated" review program by 6th January. However, Eisai will soon file for standard FDA approval of the drug and will also seek approval in Europe and Japan, regardless of the FDA's decision.
Get a daily dose of Kenya Star news through our daily email, its complimentary and keeps you fully up to date with world and business news as well.
Publish news of your business, community or sports group, personnel appointments, major event and more by submitting a news release to Kenya Star.
More InformationAlexander Dyukov has revealed Russia's football exile might end before the next World CupAlexander Dyukov, the president of the Russian ...
The country will receive a free delivery of wheat flour, Moscow's envoy has saidRussia has sent food aid to the ...
NEW YORK, 22nd September, 2023 (WAM) -- Sheikh Shakhboot bin Nahyan Al Nahyan, Minister of State, and Omar Sultan Al ...
© Provided by Xinhua Rwanda has hailed Wednesday's recognition of the country's four genocide memorial sites on the World Heritage ...
New York [US], September 22 (ANI): India has reiterated its demand for expansion of the United Nations Security Council stating ...
WASHINGTON - At the United Nations General Assembly in New York, Kenyan President William Ruto reiterated the country's commitment to ...
NAYPYIDAW, Myanmar - Aung San Suu Kyi, Myanmar's imprisoned former leader, suffers from low blood pressure symptoms such as dizziness ...
DHAKA, Bangladesh - In a tragic incident that shook the Rohingya camp at Ukhiya in Cox's Bazar, a group of ...
ISLAMABAD, Pakistan - On Monday, Pakistan's Chief Justice (CJP) Qazi Faez Isa vowed to ensure accountability and transparency, saying he ...
SYDNEY - Australian Prime Minister Anthony Albanese Thursday announced the government will conduct a yearlong inquiry into the country's approach ...
WASHINGTON - The U.S. Treasury Department on Friday said it was formally launching two new U.S.-China working groups on economic ...
After U.S. President Joe Biden told his Ukrainian counterpart, Volodymyr Zelenskiy, on September 21 that a new shipment of arms ...